source
- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalAn arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for…BioPharma Dive · 22d ago↗ source
- Another big premium hike on the horizonFDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning RoundsSTAT · 22d ago↗ source
- Opinion: STAT+: What’s the right role for AI in dementia care?Three tricky questions about using AI in dementia care.STAT · 22d ago↗ source